1268129-65-2
Chemical Structure
SDF-1α (human)
- CAS No.: 1268129-65-2
- Formula:C356H578N106O93S4
- Molecular Weight:7959.34
SMILES: O=C(N1[C@@H](CCC1)C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CSSC[C@@H](C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C(C)C)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@H]3C(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC4=O)C(N5[C@@H](CCC5)C(N[C@@H](CSSC[C@@H](C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(O)=O)C(N6[C@@H](CCC6)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CC7=CNC8=CC=CC=C78)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC9=CC=C(C=C9)O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC3=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC%10=CC=CC=C%10)C(N[C@@H](CC%11=CC=CC=C%11)C(N[C@@H](CCC(O)=O)C(N[C@@H](CO)C(N[C@@H](CC%12=CNC=N%12)C(N[C@@H](C(C)C)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CC%13=CNC=N%13)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H]([C@H](O)C)C(N%14[C@@H](CCC%14)C(N[C@H]4CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCCN)N
Biological Activity: SDF-1α (human) is an endogenous CXC chemokine and the primary natural ligand of CXCR4. SDF-1α (human) activates Gαi, MAP kinase, β-arrestin, and JAK/STAT signaling pathways, promoting chemotaxis of CXCR4-positive cells. SDF-1α (human) induces receptor internalization and promotes cancer cell migration and invasion. SDF-1α (human) promotes dental pulp cell migration and is required for osteogenesis, angiogenesis, and neurogenesis of dental pulp cells. SDF-1α (human) is used in research on CXCR4-mediated diseases, such as cancer and cardiovascular diseases[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SDF-1α (human) | SDF-1α (human) is an endogenous CXC chemokine and the primary natural ligand of CXCR4. SDF-1α (human) activates Gαi, MAP kinase, β-arrestin, and JAK/STAT signaling pathways, promoting chemotaxis of CXCR4-positive cells. SDF-1α (human) induces receptor internalization and promotes cancer cell migration and invasion. SDF-1α (human) promotes dental pulp cell migration and is required for osteogenesis, angiogenesis, and neurogenesis of dental pulp cells. SDF-1α (human) is used in research on CXCR4-mediated diseases, such as cancer and cardiovascular diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Gaonkar RH, et al. Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications. Journal of medicinal chemistry. 2023 Jul 13;66(13):8484-8497. [Content Brief]
- [2]. Katzman BM, et al. Tetrahydroisoquinoline CXCR4 Antagonists Adopt a Hybrid Binding Mode within the Peptide Subpocket of the CXCR4 Receptor. ACS medicinal chemistry letters. 2019 Jan 10;10(1):67-73. [Content Brief]
- [3]. Wang Y, et al. Development of functional poly(amido amine) CXCR4 antagonists with the ability to mobilize leukocytes and deliver nucleic acids. Advanced healthcare materials. 2015 Apr 02;4(5):729-38.
- [4]. Leng S, et al. Inflammation down regulates stromal cell-derived factor 1α in the early phase of pulpitis. Cytokine. 2022 Oct 1;158:155983.
- [5]. Mona CE, et al. Structure-Activity Relationship and Signaling of New Chimeric CXCR4 Agonists. Journal of medicinal chemistry. 2016 Aug 25;59(16):7512-24.
